{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:59:59Z","timestamp":1758398399509},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"AIRC","doi-asserted-by":"publisher","award":["AIRC 14199","AIRC 16965"],"award-info":[{"award-number":["AIRC 14199","AIRC 16965"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.lfs.2016.01.009","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T12:30:41Z","timestamp":1452256241000},"page":"43-48","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis"],"prefix":"10.1016","volume":"159","author":[{"given":"Rosanna","family":"Sestito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Cianfrocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rosan\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piera","family":"Tocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeriana","family":"Di Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Caprara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bagnato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2016.01.009_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2016.01.009_bb0010","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1078-0432.CCR-12-2243","article-title":"New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.009_bb0015","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc3546","article-title":"Endothelin 1 in cancer: biological implications and therapeutic opportunities","volume":"13","author":"Rosan\u00f2","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2016.01.009_bb0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.tips.2011.05.002","article-title":"\u03b2-Arrestin-mediated receptor trafficking and signal transduction","volume":"32","author":"Shenoy","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.lfs.2016.01.009_bb0025","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1073\/pnas.0807158106","article-title":"Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis","volume":"106","author":"Rosan\u00f2","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2016.01.009_bb0030","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1038\/onc.2012.527","article-title":"\u03b2-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced \u03b2-catenin signaling","volume":"32","author":"Rosan\u00f2","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2016.01.009_bb0035","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1158\/0008-5472.CAN-13-3133","article-title":"Endothelin A receptor\/\u03b2-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy","volume":"74","author":"Rosan\u00f2","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.009_bb0040","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0002-9440(10)64807-9","article-title":"Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo","volume":"157","author":"Salani","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lfs.2016.01.009_bb0045","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-08-1879","article-title":"Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade","volume":"69","author":"Spinella","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.009_bb0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nm1699","article-title":"Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy","volume":"14","author":"Buckanovich","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2016.01.009_bb0055","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-08-0543","article-title":"Endothelin B receptor, a new target in cancer immune therapy","volume":"15","author":"Kandalaft","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.009_bb0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1593\/neo.10806","article-title":"Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of Paclitaxel by modulating survival pathways in orthototic models of metastatic human ovarian cancer","volume":"13","author":"Kim","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.lfs.2016.01.009_bb0065","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1593\/tlo.11286","article-title":"Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist","volume":"5","author":"Kim","year":"2012","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.lfs.2016.01.009_bb0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4161\/cbt.22959","article-title":"Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells","volume":"14","author":"Coffman","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.lfs.2016.01.009_bb0075","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-3195","article-title":"Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice","author":"Kim","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.009_bb0080","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1158\/0008-5472.CAN-05-4654","article-title":"Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer","volume":"66","author":"Dome","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.009_bb0085","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","article-title":"Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry","volume":"155","author":"Maniotis","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lfs.2016.01.009_bb0090","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0002-9440(10)64079-5","article-title":"Molecular determinants of ovarian cancer plasticity","volume":"158","author":"Sood","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lfs.2016.01.009_bb0095","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4161\/cbt.316","article-title":"The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy","volume":"1","author":"Sood","year":"2002","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.lfs.2016.01.009_bb0100","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/1078-0432.CCR-10-2325","article-title":"Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells","volume":"17","author":"Rosan\u00f2","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.009_bb0105","first-page":"22850","article-title":"Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile","volume":"11","author":"Latifi","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.lfs.2016.01.009_bb0110","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2174\/156800910791190175","article-title":"Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer","volume":"10","author":"Ahmed","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.lfs.2016.01.009_bb0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc2620","article-title":"Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits","volume":"9","author":"Polyak","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2016.01.009_bb0120","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1158\/1078-0432.CCR-11-3237","article-title":"Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications","volume":"18","author":"Kirschmann","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.009_bb0125","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/IGC.0b013e3181a389e6","article-title":"Angiogenesis, vasculogenesis, and vasculogenic mimicry in ovarian cancer","volume":"19","author":"Tang","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.lfs.2016.01.009_bb0130","doi-asserted-by":"crossref","first-page":"24821","DOI":"10.1074\/jbc.M111.334540","article-title":"Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation","volume":"287","author":"Francescone","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2016.01.009_bb0135","doi-asserted-by":"crossref","first-page":"e57188","DOI":"10.1371\/journal.pone.0057188","article-title":"Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by glioma stem-like cells","volume":"8","author":"Yao","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2016.01.009_bb0140","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2016.01.009_bb0145","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2016.01.009_bb0150","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1124\/mol.61.3.524","article-title":"Endothelin-1 protects ovarian carcinoma cells against paclitaxel induced apoptosis: requirement for Akt activation","volume":"61","author":"Del Bufalo","year":"2002","journal-title":"Mol. Pharmacol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320516300108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320516300108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T04:52:48Z","timestamp":1537073568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320516300108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":30,"alternative-id":["S0024320516300108"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2016.01.009","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2016.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}